Dr. Pemmaraju is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd.
Houston, TX 77030Phone+1 713-792-2347- Is this information wrong?
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
University of Arkansas For Medical Sciences College of MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2008 - 2024
OK State Medical License 2020 - 2021- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis Start of enrollment: 2014 Dec 18
- PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2019 Sep 09
- A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy Start of enrollment: 2020 Dec 15
Publications & Presentations
PubMed
- Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.Wei-Ying Jen, Marina Konopleva, Naveen Pemmaraju> ;Cancer. 2024 Apr 15
- Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, J...> ;Cancer. 2024 Apr 9
- Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, N...> ;Haematologica. 2024 Apr 4
- Join now to see all
Journal Articles
- Characteristics of Patients with Myeloproliferative Neoplasms with Lymphoma, with or Without JAK Inhibitor TherapyNaveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Srdan Verstovsek, Blood
- International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman DiseaseAaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
Abstracts/Posters
- Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Myeloproliferative Neoplasm (MPN) Patient Online Questionnaire: Assessing PatientsÍ Disease Knowledge in a Rare Hematologic Malignancy in the Modern Digital Informatio...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Authored Content
- L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-Induced HyperbilirubinemiaFebruary 2018
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
- Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
- Join now to see all
Press Mentions
Understanding the Types of LeukemiaAugust 3rd, 2022- MD Anderson Research Highlights: ASH 2021 Special EditionDecember 8th, 2021
- Novel Antibody-Drug Conjugate Shows Promising Early Results in Rare Blood CancerDecember 7th, 2020
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
